A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

VB4-845 is a scFv-Pseudomonas exotoxin A fusion construct that targets epithelial cell adhesion molecule (EpCAM). A phase I trial was conducted to determine the maximum tolerated dose (MTD) of VB4-845 when administered as weekly intratumoral (IT) injections to patients with squamous cell carcinoma o...

Descripción completa

Detalles Bibliográficos
Autores principales: MacDonald, Glen C, Rasamoelisolo, Michèle, Entwistle, Joycelyn, Cizeau, Jeannick, Bosc, Denis, Cuthbert, Wendy, Kowalski, Mark, Spearman, Maureen, Glover, Nick
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761172/
https://www.ncbi.nlm.nih.gov/pubmed/19920898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761172/
https://www.ncbi.nlm.nih.gov/pubmed/19920898

Ejemplares similares